Alexandria Real Estate Equities, Inc 8-K, filed Mar 6, 2025
Alexandria Real Estate Equities, Inc. (ARE)
About this 8-K
Alexandria Real Estate Equities, Inc filed this 8-K on March 6, 2025, reporting on events of February 28, 2025.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including
area code: (
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4 (c)) |
Securities registered pursuant to Section 12(b) of the Exchange Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On February 28, 2025, the Board of Directors (the “Board”) of Alexandria Real Estate Equities, Inc. (the “Company”) elected Claire Aldridge, Ph.D., as a director of the Company, effective March 14, 2025, to serve until the 2025 annual meeting of stockholders of the Company and until her successor is duly elected and qualifies. In connection with Dr. Aldridge’s election, the Board increased the size of the Board from eight to nine directors. The Board also appointed Dr. Aldridge as a member of its Life Science Committee and determined that Dr. Aldridge is independent in accordance with applicable New York Stock Exchange listing standards and Securities and Exchange Commission rules. There were no arrangements or understandings between Dr. Aldridge and any other persons regarding her election to the Board. Dr. Aldridge is not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Dr. Aldridge was the Chief Strategy Officer of Form Bio, Inc. (“Form Bio”), the first spinout from the de-extinction and biodiversity company Colossal Biosciences Inc., from July 2022 to August 2024. At Form Bio, Dr. Aldridge led the integration of artificial intelligence (AI) and machine learning into genomic analysis and advanced therapeutics programs, such as gene therapy, biological sequence alignment, and directed evolution, to accelerate the development of safe and effective new medicines. She also oversaw the generation of vast proprietary datasets needed to train sophisticated AI models.
Dr. Aldridge currently serves on the Scientific Advisory Board of Colossal Biosciences and on the board of directors of 4E Therapeutics, Inc. She sits on the Product Development Advisory Committee of the Cancer Prevention and Research Institute of Texas (CPRIT), the $6 billion state agency established to help Texans conquer cancer through research, prevention and commercialization. Dr. Aldridge is also a founding advisor for Nucleate Texas, a non-profit organization empowering the next generation of biotechnology leaders. Additionally, she participates in Duke University’s Entrepreneurial Leaders Network, which consists of a select group of Duke students and alumni who are focused on translating Duke discoveries into innovative startups, and is Past Chair of the Industrial Advisory Board of the Department of Bioengineering at The University of Texas at Dallas. In April 2023, Dr. Aldridge was named one of Forbes’ 10 women leading the synthetic biology revolution.
Previously, Dr. Aldridge served as Senior Vice President, Chief of Staff and Business Operations at Taysha Gene Therapies, Inc. from July 2021 to April 2022; as Associate Vice President of Commercialization and Business Development at The University of Texas Southwestern Medical Center from April 2019 to February 2021; and as Vice President, Venture Development at Remeditex Ventures from July 2011 to April 2019.
Dr. Aldridge brings more than 25 years of experience facilitating the translation of scientific discoveries into patient and commercial benefits and has leveraged her training to be a liaison between scientists and non-scientists. Her roles have included biotechnology and life science investing through venture capital; technology commercialization; improving patient outcomes through quality-based initiatives; working with disease-specific non-profits; and development and venture philanthropy.
Dr. Aldridge received her Ph.D. from Duke University in the Department of Immunology and the Program in Genetics and Genomics and her Bachelor of Science degree in Biomedical Science from Texas A&M University.
Upon her initial election to the Board and pursuant to the terms of the Company’s Amended and Restated 1997 Stock Award and Incentive Plan, Dr. Aldridge will receive a grant of 1,000 shares of restricted stock of the Company, which shares will vest in full on the second anniversary of the date of grant. Dr. Aldridge will also generally participate in the compensation arrangements provided to the Company’s independent directors, as described in the Company’s Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on April 3, 2024, under the caption “2023 Director Compensation Table.”
The press release announcing Dr. Aldridge’s election as a director of the Company is attached hereto as Exhibit 99.1 and is filed herewith.
| Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits
| 99.1 | Press Release, dated March 6, 2025. | |
| 104.1 | Cover Page Interactive Data File – the cover page XBRL tags are embedded within the Inline XBRL document. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ALEXANDRIA REAL ESTATE EQUITIES, INC. | ||
| March 6, 2025 | By: | /s/ Marc E. Binda |
| Marc E. Binda | ||
| Chief Financial Officer and Treasurer | ||
Exhibit 99.1
Alexandria Real Estate Equities, Inc. Elects Claire Aldridge, PhD, to Board of Directors
PASADENA, Calif., March 6, 2025 – Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science innovation cluster locations, today announced that the company’s board of directors has elected Claire Aldridge, PhD, as an independent director, effective March 14, 2025. The board of directors has also appointed Dr. Aldridge to serve as a member of its Life Science Committee and determined that she is independent in accordance with New York Stock Exchange listing standards and Securities and Exchange Commission rules. Her term will run until the company’s 2025 annual meeting of stockholders.
“Dr. Aldridge’s distinguished career in the life science industry spans more than 25 years across biotechnology, venture capital, entrepreneurship, technology commercialization and AI-accelerated therapeutic development,” said Joel S. Marcus, executive chairman and founder of Alexandria Real Estate Equities, Inc. and Alexandria Venture Investments. “Her deep business and scientific experience, which includes facilitating the translation of scientific discoveries into innovative therapies that improve patient lives, will further bolster the combined expertise of our board, and we are honored to welcome her.”
Dr. Aldridge was the chief strategy officer of Form Bio, the first spinout from the de-extinction and biodiversity company Colossal Biosciences. At Form Bio, Dr. Aldridge led the integration of artificial intelligence and machine learning into genomic analysis and advanced therapeutics programs, such as gene therapy, biological sequence alignment and directed evolution, to accelerate the development of safe and effective new medicines. She also oversaw the generation of vast proprietary datasets needed to train sophisticated AI models. Prior to Form Bio, Dr. Aldridge served as senior vice president, chief of staff and business operations at Taysha Gene Therapies, a clinical-stage biotechnology company focused on advancing gene therapies for severe monogenic diseases of the central nervous system. She was previously associate vice president of commercialization and business development at UT Southwestern Medical Center and vice president of venture development at Remeditex Ventures.
Dr. Aldridge currently serves on the scientific advisory board of Colossal Biosciences and on the board of directors of 4E Therapeutics. She is also a member of the Product Development Advisory Committee of the Cancer Prevention and Research Institute of Texas (CPRIT), the $6 billion state agency established to help Texans conquer cancer; a founding advisor for Nucleate Texas, a non-profit organization dedicated to empowering the next generation of biotechnology leaders; a participant in Duke University’s Entrepreneurial Leaders Network; and past chair of the Industrial Advisory Board of Bioengineering at UT Dallas. In April 2023, she was named one of Forbes’ 10 women leading the synthetic biology revolution.
Dr. Aldridge received her PhD from Duke University in the Department of Immunology and the Program in Genetics and Genomics and her Bachelor of Science degree in Biomedical Science from Texas A&M University.
About Alexandria Real Estate Equities, Inc.
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle and New York City. As of December 31, 2024, Alexandria has a total market capitalization of $29.0 billion and an asset base in North America that includes 39.8 million RSF of operating properties and 4.4 million RSF of Class A/A+ properties undergoing construction. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in highly dynamic and collaborative Megacampus environments that enhance our tenants’ ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns and greater long-term asset value. For more information on Alexandria, please visit www.are.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding the potential impacts of a director’s appointment to the company’s board of directors and expectations regarding the company’s performance and success. These forward-looking statements are based on Alexandria’s present intent, beliefs or expectations, but forward-looking statements are not guaranteed to occur and may not occur. Actual results may differ materially from those contained in or implied by Alexandria’s forward-looking statements as a result of a variety of factors, including, without limitation, the risks and uncertainties detailed in its filings with the Securities and Exchange Commission. All forward-looking statements are made as of the date of this press release, and Alexandria assumes no obligation to update this information. For more discussion relating to risks and uncertainties that could cause actual results to differ materially from those anticipated in Alexandria’s forward-looking statements, and risks and uncertainties to Alexandria’s business in general, please refer to Alexandria’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q.
CONTACT: Sara Kabakoff, Senior Vice President – Chief Content Officer, (626) 788-5578,
skabakoff@are.com
###